Pelthos Therapeutics Inc (PTHS)

Currency in USD
21.360
+0.850(+4.14%)
Real-time Data·
PTHS Scorecard
Full Analysis
Significant return over the last week
Earnings results expected in 14 days
PTHS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
20.75021.540
52 wk Range
4.50054.290
Key Statistics
Prev. Close
20.51
Open
21.27
Day's Range
20.75-21.54
52 wk Range
4.5-54.29
Volume
3.1K
Average Volume (3m)
61.1K
1-Year Change
165.23%
Book Value / Share
-9.85
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PTHS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
60.000
Upside
+180.90%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with high price volatility

Pelthos Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Pelthos Therapeutics Inc Company Profile

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.

Employees
8

Compare PTHS to Peers and Sector

Metrics to compare
PTHS
Peers
Sector
Relationship
P/E Ratio
−1.5x−3.0x−0.6x
PEG Ratio
−0.030.020.00
Price/Book
−2.1x1.8x2.6x
Price / LTM Sales
-8.8x3.3x
Upside (Analyst Target)
192.5%201.9%40.1%
Fair Value Upside
Unlock4.2%5.3%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 60.000
(+180.90% Upside)

Earnings

Latest Release
May 28, 2025
EPS / Forecast
-3.21 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

PTHS Income Statement

People Also Watch

20.30
SRPT
+0.59%
2.170
VOR
+5.85%
50.66
BMNR
+1.77%
0.107
WINT
-77.94%

FAQ

What Stock Exchange Does Pelthos Therapeutics Trade On?

Pelthos Therapeutics is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Pelthos Therapeutics?

The stock symbol for Pelthos Therapeutics is "PTHS."

What Is the Pelthos Therapeutics Market Cap?

As of today, Pelthos Therapeutics market cap is 13.82M.

What Is Pelthos Therapeutics's Earnings Per Share (TTM)?

The Pelthos Therapeutics EPS (TTM) is -14.84.

When Is the Next Pelthos Therapeutics Earnings Date?

Pelthos Therapeutics will release its next earnings report on 02 Sept 2025.

From a Technical Analysis Perspective, Is PTHS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Pelthos Therapeutics Stock Split?

Pelthos Therapeutics has split 1 times.

How Many Employees Does Pelthos Therapeutics Have?

Pelthos Therapeutics has 8 employees.

What is the current trading status of Pelthos Therapeutics (PTHS)?

As of 20 Aug 2025, Pelthos Therapeutics (PTHS) is trading at a price of 21.36, with a previous close of 20.51. The stock has fluctuated within a day range of 20.75 to 21.54, while its 52-week range spans from 4.50 to 54.29.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.